Remove Access Remove Cannabis Remove Treatment Remove Events
article thumbnail

Curaleaf International Advances Accessibility of Medical Cannabis Products in Germany with Strategic Partnership

Cannabis Law Report

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. billion 1 by 2025.

Access 105
article thumbnail

Press Release: Launch of the Psychedelic Access and Research European Alliance – PAREA

Cannabis Law Report

Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD. However, there is a growing realization that European health systems may not be prepared for these treatments. Psychedelic compounds – such as psilocybin and MDMA – are one such extremely promising area.

Access 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

A team of Israeli researchers conducted a randomized placebo-controlled clinical trial to assess the safety and efficacy of a novel, metered-dose cannabis inhaler in 27 patients with chronic pain. Adverse events were mostly mild and resolved spontaneously. The 1mg dose showed a significant pain decrease compared to the placebo.

article thumbnail

New Research Shows How Medicinal Cannabis Eases Cancer Pain and Reduces Opioid Dependence

Veriheal

But what if a safe and effective complementary plant-based treatment was widely available to alleviate cancer pain? A new 2023 study published in BMJ Supportive & Palliative Care suggests that cannabis could be the answer millions of cancer patients have been looking for. in cancer patients undergoing anticancer treatment, 50.7%

article thumbnail

Mind Medicine Australia – Opinion: If the Medicine Works Shouldn’t We All Have Access to it? A Recent Poll of Australians Says Yes We Should – Scott Leckie and Tania de Jong (February 2022)

Cannabis Law Report

Our families and communities are suffering, and we urgently need access to preventative and curative medicines and medical care that is safe and effective. These ground-breaking treatments offer therapeutic access to either psilocybin (the active ingredient in ‘magic mushrooms’) or MDMA, a synthetic medicine.

article thumbnail

New Issue of the ASA Activist Newsletter is out!

Americans for Safe Access

Updates include important federal cannabis reforms that have been signed into law or are pending before Congress, as well as PFC's new role as a GMP Certifier in New York state, a new episode of the Cannabis Enigma podcast, and a sneak peek at the revamped state report card.

Events 158
article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.